RE:RE:RE:Cash CPA Trader:
I had PLI with cash on a proforma basis of $ approx 97 million at the end of Q3 as follows:
Q3 Cash as reported $39 million
Cash from Telesta acquisition $37 million
PSS Warrant exercise $21 million
Total $97 million
This would buy PLI a years worth of existence assuming a $25 million per quarter cash burn or
end of Q3/17
So with the Thomvest loan, PLI has cash to the end of 2017 before factoring in the Plasminogen
launch.
I suppose the above lines up with a NASDAQ listing in Q3/17 (some share consolidation happens too I think) and a big capital raise to fund further expansion of the drug pipeline value.
Hope this helps
Coyote13